STEGLATRO 5 mg/1 (Ertugliflozin TABLET, FILM COATED) 5 mg/1

STEGLATRO 5 mg is a medication containing ertugliflozin, used to manage type 2 diabetes. This oral tablet helps control blood sugar levels as part of a broader treatment plan.

Strength

5 mg/1

Pack Size

2 BOTTLE in 1 CARTON (0006-5363-09) / 7 TABLET, FILM COATED in 1 BOTTLE (0006-5363-08)

Manufacturer / TM Owner

Merck Sharp & Dohme LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

STEGLATRO 5 mg is primarily used to manage type 2 diabetes in adults. It works by helping the kidneys remove excess glucose from the body through urine. This medication is often used alongside diet and exercise to improve glycemic control. People may ask, 'What is STEGLATRO used for?' and the answer is managing type 2 diabetes.

Side Effects

Common effects of STEGLATRO 5 mg may include urinary tract infections, increased urination, and changes in urination patterns. Some individuals might experience symptoms like thirst or dizziness. These effects vary and are not experienced by everyone.

Precautions & Warnings

STEGLATRO 5 mg should be handled with care, especially for those with a history of kidney issues or diabetic ketoacidosis. It is important to stay hydrated while using this medication. Always follow the advice of a healthcare provider regarding its use.

Avoid Interactions

STEGLATRO 5 mg may interact with certain medications, including insulin and other diabetes treatments. Alcohol consumption should be moderated, as it can affect blood sugar levels. Always inform your healthcare provider about all medications you are taking.

Frequently Asked Questions

STEGLATRO is used to manage type 2 diabetes in adults by helping the kidneys remove excess glucose.

STEGLATRO is taken orally, typically once daily. Always follow the instructions provided by your healthcare provider.

Common side effects may include urinary tract infections, increased urination, and symptoms like thirst or dizziness.

STEGLATRO may be used with other diabetes medications, but always consult your healthcare provider to avoid potential interactions.

STEGLATRO is not suitable for everyone. Those with a history of kidney issues or diabetic ketoacidosis should use it with caution.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.